Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
30 juil. 2019 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, July 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain
03 juil. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, July 03, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Holding Ltd Provides Corporate Update
23 mai 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, May 23, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain
07 mai 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, May 07, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...